ClinicalTrials.gg
CompletedNCT04168190Updated Sep 16, 2022Results posted

A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)

A Phase 1/2 interventional study of V116 and Pneumovax™23 in Pneumonia, Pneumococcal, sponsored by Merck Sharp & Dohme LLC. Completed at 20 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-16.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Pneumonia, Pneumococcal with a site in United States — none open to participants now, none under way, none of them phase 3. Pneumonia, Pneumococcal · United States.

Enrollment
5th of 11
600 · median 431
Started
2019
with 1 other
Phase 1/2
Only one
of the 12
Registered
7th of 12
by date
Lead sponsor
4 of 12
Merck Sharp & Dohme LLC

Among the 12 studies in Pneumonia, Pneumococcal with a site in United States, this one is the 5th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2019, is the only one in phase 1/2, and was the 7th registered.

Pneumonia, Pneumococcal

44 studies on the registry are indexed under Pneumonia, Pneumococcal; 2 are open to participants now.

Browse Pneumonia, Pneumococcal studies →

Open to participants now

None of the 12 studies in Pneumonia, Pneumococcal with a site in United States is open now. The open studies under Pneumonia, Pneumococcal, anywhere →

Who these studies take

Of the 1 Pneumonia, Pneumococcal study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Pneumonia, Pneumococcal with a site in United States as a file.
02

Study summary

This Phase 1 and Phase 2 study will evaluate the safety, tolerability and immunogenicity of V116 when administered to adults. Phase 1 has no formal hypothesis. The primary hypotheses for Phase 2 are: V116 is noninferior to Pneumovax™23 as measured by the serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) for the common serotypes at 30 days postvaccination and that the serotype-specific OPA GMTs for the unique serotypes in V116 at 30 days postvaccination are statistically significantly greater following vaccination with V116 than those following vaccination with Pneumovax™23.

03

Conditions studied

  • Pneumonia, Pneumococcal
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Phase 1:
  • Male or female, from 18 years to 49 years of age inclusive
  • Phase 2:
  • Male or female ≥50 years of age Phase 1 and Phase 2
  • Males: refrain from donating sperm, remain abstinent during study or agree to use condom
  • Females: Not pregnant. If a woman of , agree to use or remain abstinent

Exclusion criteria

Exclusion Criteria

  • History of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease within 3 years of screening
  • Known to any component of the pPCV, or any diphtheria toxoid-containing vaccine
  • Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented (HIV) infection, functional or anatomic asplenia, or history of disease
  • Coagulation disorder contraindicating IM vaccination
  • Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring within 72 hours of screening
  • Known that is progressing or has required active treatment within 3 years.(Note: participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ [eg, breast carcinoma, cervical cancer in situ] that have undergone potentially curative therapy are not excluded)
  • Pregnant
  • Received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study, outside of the protocol.
  • Receiving therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease
  • Received a blood transfusion or blood products, including immunoglobulin, 6 months before study vaccination or is scheduled to receive a blood transfusion or blood product
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
600 participants (actual)

Study arms

  • Experimental
    Phase 1: V116 0.5 mL

    Participants will receive a single intramuscular (IM) 0.5 mL vaccination on Day 1 of Phase 1

    Biological: V116

  • Experimental
    Phase 1: V116 1.0 mL

    Participants will receive a single IM 1.0 mL vaccination on Day 1 of Phase 1

    Biological: V116

  • Active comparator
    Phase 1: Pneumovax™23

    Participants will receive a single IM 0.5 mL vaccination on Day 1 of Phase 1

    Biological: Pneumovax™23

  • Experimental
    Phase 2: V116

    Participants will receive a single IM 1.0 mL vaccination on Day 1 of Phase 2

    Biological: V116

  • Active comparator
    Phase 2: Pneumovax™23

    Participants will receive a single IM 0.5 mL vaccination on Day 1 of Phase 2

    Biological: Pneumovax™23

Interventions

  • BiologicalV116

    Pneumococcal 21-valent conjugate vaccine with 2 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

    Also known as: Polyvalent pneumococcal conjugate vaccine (pPCV), Pneumococcal 21-valent Conjugate Vaccine

  • BiologicalPneumovax™23

    Drug page: 23-valent pneumococcal capsular polysaccharide vaccine

    Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution

    Also known as: PPSV23

06

What researchers measure

Primary outcomes

  1. Phase 1: Percentage of Participants With a Solicited Injection-site Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Injection-site AEs solicited on the Vaccine Report Card (VRC) were redness/erythema, swelling, and tenderness/pain. The percentage of participants with one or more solicited injection-site AE was assessed.

    Time frame: Up to 5 days post-vaccination

  2. Phase 1: Percentage of Participants With a Solicited Systemic AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Systemic AEs solicited on the VRC were muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue. The percentage of participants with one or more solicited systemic AE was assessed.

    Time frame: Up to 5 days post-vaccination

  3. Phase 1: Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs)

    A serious adverse event (SAE) is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. The percentage of participants with one or more SAE that were assessed by the investigator to be at least possibly related to the study vaccination were reported.

    Time frame: Up to Day 195

  4. Phase 2: Percentage of Participants With a Solicited Injection-site AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Injection-site AEs solicited on the Vaccine Report Card (VRC) were redness/erythema, swelling, and tenderness/pain. The percentage of participants with one or more solicited injection-site AE was assessed.

    Time frame: Up to 5 days post-vaccination

  5. Phase 2: Percentage of Participants With a Solicited Systemic AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Systemic AEs solicited on the VRC were muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue. The percentage of participants with 1 or more solicited systemic AE was assessed.

    Time frame: Up to 5 days post-vaccination

  6. Phase 2: Percentage of Participants With Vaccine-related SAEs

    An SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. The percentage of participants who experienced at least one SAE that were assessed by the investigator to be at least possibly related to the study vaccination were reported.

    Time frame: Up to Day 293

  7. Phase 2: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the Common Serotypes in V116 and Pneumovax™23

    GMTs for the serotypes common to V116 and Pneumovax™23 were determined using the muliplex opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals (CIs) were calculated using a constrained longitudinal data analysis (cLDA) model. Per protocol, within-group CIs were not calculated.

    Time frame: 30 days post vaccination

  8. Phase 2: Serotype-specific OPA GMTs for the Unique Serotypes in V116

    GMTs for the serotypes unique to V116 were determined using the MOPA. Serotype-specific OPA GMTs and GMT ratios with 95% CIs were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.

    Time frame: 30 days post vaccination

Secondary outcomes

  1. Phase 1: Serotype-specific Immunoglobin G (IgG) Geometric Mean Concentrations (GMCs) for the Common Serotypes in V116 and Pneumovax™23

    Serotype-specific pneumococcal IgG antibodies were measured using pneumococcal electrochemiluminescence (PnECL). Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.

    Time frame: 30 days post vaccination

  2. Phase 1: Serotype-specific Immunoglobin G (IgG) Geometric Mean Concentrations (GMCs) for the Serotypes Unique to V116

    Serotype-specific pneumococcal IgG antibodies were measured using PnECL. Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.

    Time frame: 30 days post vaccination

  3. Phase 1: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the Common Serotypes in V116 and Pneumovax™23

    GMTs for the serotypes common to V116 and Pneumovax™23 were determined using the MOPA. Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.

    Time frame: 30 days post vaccination

  4. Phase 1: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the Unique Serotypes in V116 and Pneumovax™23

    GMTs for the serotypes common to V116 and Pneumovax™23 were determined using the MOPA. Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.

    Time frame: 30 days post vaccination

  5. Phase 1: Geometric Mean Fold Rise (GMFR) From Baseline in GMTs of Serotype-specific OPA

    GMTs for the serotypes in V116 and Pneumovax™23 were determined using the MOPA at baseline and 30 days post vaccination and derived from a cLDA model. The GMFR (Day 30 GMT/Day 1 GMT) from baseline (Day 1) to Day 30 of each pneumococcal IgG serotype was calculated.

    Time frame: Baseline (Day 1) and 30 days postvaccination

  6. Phase 1: Geometric Mean Fold Rise (GMFR) From Baseline in GMCs of Serotype-specific IgG

    GMCs for the serotypes in V116 and Pneumovax™23 were measured by PnECL at baseline and 30 days post vaccination and derived from a cLDA model. The GMFR (Day 30 GMC/Day 1 GMC) from baseline (Day 1) to Day 30 of each pneumococcal IgG serotype was calculated.

    Time frame: Baseline (Day 1) and 30 days post vaccination

  7. Phase 2: Serotype-specific IgG GMCs for the Common Serotypes in V116 and Pneumovax™23

    Serotype-specific pneumococcal IgG antibodies were measured using PnECL. Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.

    Time frame: 30 days post vaccination

  8. Phase 2: Serotype-specific IgG GMCs for the Serotypes Unique to V116

    Serotype-specific pneumococcal IgG antibodies were measured using PnECL. Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.

    Time frame: 30 days post vaccination

  9. Phase 2: Geometric Mean Fold Rise (GMFR) From Baseline in GMTs of Serotype-specific OPA

    GMTs for the serotypes in V116 and Pneumovax™23 were determined using the MOPA at baseline and at 30 days post vaccination and derived from a cLDA model. The GMFR for each pneumococcal IgG serotype was calculated as Day 30 GMT/Day 1 GMT.

    Time frame: Baseline (Day 1) and 30 days post vaccination

  10. Phase 2: GMFR From Baseline in GMCs of Serotype-specific IgG

    GMCs for each serotype common in V116 and Pneumovax™23 were measured using PnECL at baseline and 30 days post vaccination and derived from a cLDA model. The GMFR for each pneumococcal IgG serotype was calculated as Day 30 GMC/Day 1 GMC.

    Time frame: Baseline (Day 1) and 30 days post vaccination

  11. Phase 2: Percentage of Participants Who Achieve a ≥4-fold Increase in Serotype-specific OPA Responses From Prevaccination (Baseline [Day 1]) to 30 Days Post Vaccination

    The percentage of participants with ≥4-fold rise from baseline (Day 1) to Day 30 in GMTs of each pneumococcal serotype was calculated. Titer levels were determined by the MOPA and derived from a cLDA model.

    Time frame: Baseline (Day 1) and 30 days post vaccination

07

Results

Posted Aug 2, 2022

Participant flow

Participant flow — Overall Study
MilestonePhase 1: V116 0.5 mLPhase 1: V116 1.0 mLPhase 1: Pneumovax™23Phase 2: V116Phase 2: Pneumovax™23
Started303030254256
Treated303030254254
Completed292930244247
Not completed110109
Withdrew: Lost to follow-up01075
Withdrew: Withdrawal by subject10024
Withdrew: Death00010

Outcome measures

PrimaryPhase 1: Percentage of Participants With a Solicited Injection-site Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Injection-site AEs solicited on the Vaccine Report Card (VRC) were redness/erythema, swelling, and tenderness/pain. The percentage of participants with one or more solicited injection-site AE was assessed.

Time frame:
Up to 5 days post-vaccination
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants With a Solicited Injection-site Adverse Event (AE)
Percentage of participantsPhase 1: V116 0.5 mLPhase 1: V116 1.0 mLPhase 1: Pneumovax™23
Injection site erythema10.023.320.0
Injection site pain73.376.756.7
Injection site swelling20.016.713.3
Statistical analysis
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Difference in percentage: -10.0 · 95% CI -29.3 to 9.0Phase 1: V116 0.5 mL minus Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Difference in percentage: 3.3 · 95% CI -18.1 to 24.6Phase 1: V116 1.0 mL minus Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Difference in percentage: 16.7 · 95% CI -7.7 to 39.3Phase 1: V116 0.5 mL minus Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Difference in percentage: 20.0 · 95% CI -4.1 to 42.1Phase 1: V116 1.0 mL minus Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Difference in percentage: 6.7 · 95% CI -13.2 to 26.5Phase 1: V116 0.5 mL minus Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Difference in percentage: 3.3 · 95% CI -16.0 to 22.8Phase 1: V116 1.0 mL minus Phase 1: Pneumovax™23
PrimaryPhase 1: Percentage of Participants With a Solicited Systemic AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Systemic AEs solicited on the VRC were muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue. The percentage of participants with one or more solicited systemic AE was assessed.

Time frame:
Up to 5 days post-vaccination
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants With a Solicited Systemic AE
Percentage of participantsPhase 1: V116 0.5 mLPhase 1: V116 1.0 mLPhase 1: Pneumovax™23
Fatigue26.726.716.7
Arthralgia16.710.06.7
Myalgia26.730.013.3
Headache30.020.016.7
Statistical analysis
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Difference in percentage: 10.0 · 95% CI -11.4 to 31.0Phase 1: V116 0.5 mL minus Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Difference in percentage: 10.0 · 95% CI -11.4 to 31.0Phase 1: V116 1.0 mL minus Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Difference in percentage: 10.0 · 95% CI -7.4 to 28.3Phase 1: V116 0.5 mL minus Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Difference in percentage: 3.3 · 95% CI -13.1 to 20.2Phase 1: V116 1.0 mL minus Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Difference in percentage: 13.3 · 95% CI -7.5 to 33.8Phase 1: V116 0.5 mL minus Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Difference in percentage: 16.7 · 95% CI -4.6 to 37.3Phase 1: V116 1.0 mL minus Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Difference in percentage: 13.3 · 95% CI -8.5 to 34.5Phase 1: V116 0.5 mL minus Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Difference in percentage: 3.3 · 95% CI -17.2 to 23.8Phase 1: V116 1.0 mL minus Phase 1: Pneumovax™23
PrimaryPhase 1: Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs)

A serious adverse event (SAE) is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. The percentage of participants with one or more SAE that were assessed by the investigator to be at least possibly related to the study vaccination were reported.

Time frame:
Up to Day 195
Reported as:
Number · Percentage of participants
Phase 1: Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs)
Percentage of participantsPhase 1: V116 0.5 mLPhase 1: V116 1.0 mLPhase 1: Pneumovax™23
Phase 1: Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs)0.00.00.0
Statistical analysis
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Difference in percentage: 0.0 · 95% CI -11.5 to 11.5Phase 1: V116 0.5 mL minus Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Difference in percentage: 0.0 · 95% CI -11.5 to 11.5Phase 1: V116 1.0 mL minus Phase 1: Pneumovax™23
PrimaryPhase 2: Percentage of Participants With a Solicited Injection-site AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Injection-site AEs solicited on the Vaccine Report Card (VRC) were redness/erythema, swelling, and tenderness/pain. The percentage of participants with one or more solicited injection-site AE was assessed.

Time frame:
Up to 5 days post-vaccination
Reported as:
Number · Percentage of Participants
Phase 2: Percentage of Participants With a Solicited Injection-site AE
Percentage of ParticipantsPhase 2: V116Phase 2: Pneumovax™23
Injection site erythema8.76.7
Injection site pain46.537.8
Injection site swelling11.07.9
Statistical analysis
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · Difference in percentage: 2.0 · 95% CI -2.8 to 6.8Phase 2: V116 minus Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · Difference in percentage: 8.7 · 95% CI 0.1 to 17.1Phase 2: V116 minus Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · Difference in percentage: 3.1 · 95% CI -2.0 to 8.4Phase 2: V116 minus Phase 2: Pneumovax™23
PrimaryPhase 2: Percentage of Participants With a Solicited Systemic AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Systemic AEs solicited on the VRC were muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue. The percentage of participants with 1 or more solicited systemic AE was assessed.

Time frame:
Up to 5 days post-vaccination
Reported as:
Number · Percentage of Participants
Phase 2: Percentage of Participants With a Solicited Systemic AE
Percentage of ParticipantsPhase 2: V116Phase 2: Pneumovax™23
Fatigue19.312.2
Arthralgia4.34.3
Myalgia11.09.4
Headache16.913.4
Statistical analysis
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · Difference in percentage: 7.1 · 95% CI 0.8 to 13.5Phase 2: V116 minus Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · Difference in percentage: 0.0 · 95% CI -3.8 to 3.8Phase 2: V116 minus Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · Difference in percentage: 1.6 · 95% CI -3.8 to 7.0Phase 2: V116 minus Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · Difference in percentage: 3.5 · 95% CI -2.7 to 9.9Phase 2: V116 minus Phase 2: Pneumovax™23
PrimaryPhase 2: Percentage of Participants With Vaccine-related SAEs

An SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. The percentage of participants who experienced at least one SAE that were assessed by the investigator to be at least possibly related to the study vaccination were reported.

Time frame:
Up to Day 293
Reported as:
Number · Percentage of Participants
Phase 2: Percentage of Participants With Vaccine-related SAEs
Percentage of ParticipantsPhase 2: V116Phase 2: Pneumovax™23
Phase 2: Percentage of Participants With Vaccine-related SAEs0.00.0
Statistical analysis
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · Difference in percentage: 0.0 · 95% CI -1.5 to 1.5Phase 2: V116 minus Phase 2: Pneumovax™23
PrimaryPhase 2: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the Common Serotypes in V116 and Pneumovax™23

GMTs for the serotypes common to V116 and Pneumovax™23 were determined using the muliplex opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals (CIs) were calculated using a constrained longitudinal data analysis (cLDA) model. Per protocol, within-group CIs were not calculated.

Time frame:
30 days post vaccination
Reported as:
Geometric mean · Titers
Phase 2: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the Common Serotypes in V116 and Pneumovax™23
TitersPhase 2: V116Phase 2: Pneumovax™23
Serotype 3226.26 (NA to NA)226.21 (NA to NA)
Serotype 7F3535.44 (NA to NA)2906.76 (NA to NA)
Serotype 19A2388.12 (NA to NA)2116.13 (NA to NA)
Serotype 22F8213.56 (NA to NA)5192.20 (NA to NA)
Serotype 33F28129.21 (NA to NA)29974.55 (NA to NA)
Serotype 81504.65 (NA to NA)1526.78 (NA to NA)
Serotype 9N10327.15 (NA to NA)9106.32 (NA to NA)
Serotype 10A6062.22 (NA to NA)5092.07 (NA to NA)
Serotype 11A2840.38 (NA to NA)1252.27 (NA to NA)
Serotype 12F2549.45 (NA to NA)991.10 (NA to NA)
Serotype 17F18394.13 (NA to NA)11249.90 (NA to NA)
Serotype 20A9305.32 (NA to NA)5068.03 (NA to NA)
Statistical analysis
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmt ratio: 1.00 · 95% CI 0.82 to 1.22Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmt ratio: 1.22 · 95% CI 0.95 to 1.56Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmt ratio: 1.13 · 95% CI 0.90 to 1.41Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmt ratio: 1.58 · 95% CI 1.16 to 2.16Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmt ratio: 0.94 · 95% CI 0.71 to 1.24Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmt ratio: 0.99 · 95% CI 0.80 to 1.21Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmt ratio: 1.13 · 95% CI 0.87 to 1.47Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmt ratio: 1.19 · 95% CI 0.93 to 1.52Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmt ratio: 2.27 · 95% CI 1.78 to 2.90Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmt ratio: 2.57 · 95% CI 1.86 to 3.55Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmt ratio: 1.64 · 95% CI 1.24 to 2.16Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmt ratio: 1.84 · 95% CI 1.43 to 2.36Phase 2: V116/Phase 2: Pneumovax™23
PrimaryPhase 2: Serotype-specific OPA GMTs for the Unique Serotypes in V116

GMTs for the serotypes unique to V116 were determined using the MOPA. Serotype-specific OPA GMTs and GMT ratios with 95% CIs were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.

Time frame:
30 days post vaccination
Reported as:
Geometric mean · Titers
Phase 2: Serotype-specific OPA GMTs for the Unique Serotypes in V116
TitersPhase 2: V116Phase 2: Pneumovax™23
Serotype 6A2757.55 (NA to NA)456.97 (NA to NA)
Serotype 15A11640.00 (NA to NA)1711.40 (NA to NA)
Serotype 15C12611.76 (NA to NA)4200.74 (NA to NA)
Serotype 16F9820.72 (NA to NA)539.16 (NA to NA)
Serotype 23A11554.45 (NA to NA)593.91 (NA to NA)
Serotype 23B3137.15 (NA to NA)105.00 (NA to NA)
Serotype 24F7640.78 (NA to NA)238.65 (NA to NA)
Serotype 314461.98 (NA to NA)127.84 (NA to NA)
Serotype 35B15704.65 (NA to NA)1745.16 (NA to NA)
Statistical analysis
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmt ratio: 6.03 · 95% CI 4.23 to 8.62Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmt ratio: 6.80 · 95% CI 5.37 to 8.62Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmt ratio: 3.00 · 95% CI 2.31 to 3.90Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmt ratio: 18.21 · 95% CI 12.98 to 25.57Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmt ratio: 19.45 · 95% CI 12.87 to 29.40Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmt ratio: 29.88 · 95% CI 20.72 to 43.09Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmt ratio: 32.02 · 95% CI 22.83 to 44.89Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmt ratio: 34.90 · 95% CI 24.25 to 50.23Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmt ratio: 9.00 · 95% CI 7.19 to 11.26Phase 2: V116/Phase 2: Pneumovax™23
SecondaryPhase 1: Serotype-specific Immunoglobin G (IgG) Geometric Mean Concentrations (GMCs) for the Common Serotypes in V116 and Pneumovax™23

Serotype-specific pneumococcal IgG antibodies were measured using pneumococcal electrochemiluminescence (PnECL). Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.

Time frame:
30 days post vaccination
Reported as:
Geometric mean · μg/mL
Phase 1: Serotype-specific Immunoglobin G (IgG) Geometric Mean Concentrations (GMCs) for the Common Serotypes in V116 and Pneumovax™23
μg/mLPhase 1: V116 0.5 mLPhase 1: V116 1.0 mLPhase 1: Pneumovax™23
Serotype 30.78 (NA to NA)0.97 (NA to NA)0.86 (NA to NA)
Serotype 7F3.33 (NA to NA)6.39 (NA to NA)2.98 (NA to NA)
Serotype 19A6.29 (NA to NA)10.27 (NA to NA)4.93 (NA to NA)
Serotype 22F5.27 (NA to NA)7.14 (NA to NA)7.16 (NA to NA)
Serotype 33F8.64 (NA to NA)15.19 (NA to NA)11.51 (NA to NA)
Serotype 811.33 (NA to NA)17.62 (NA to NA)17.80 (NA to NA)
Serotype 9N5.40 (NA to NA)8.60 (NA to NA)5.26 (NA to NA)
Serotype 10A8.90 (NA to NA)13.13 (NA to NA)7.15 (NA to NA)
Serotype 11A4.50 (NA to NA)9.44 (NA to NA)5.93 (NA to NA)
Serotype 12F1.03 (NA to NA)2.13 (NA to NA)0.99 (NA to NA)
Serotype 17F11.54 (NA to NA)15.71 (NA to NA)5.48 (NA to NA)
Serotype 20A16.44 (NA to NA)19.13 (NA to NA)9.97 (NA to NA)
Statistical analysis
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 0.91 · 95% CI 0.58 to 1.42Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 1.12 · 95% CI 0.71 to 1.76Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 1.12 · 95% CI 0.63 to 1.99Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 2.14 · 95% CI 1.19 to 3.84Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 1.27 · 95% CI 0.74 to 2.21Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 2.08 · 95% CI 1.19 to 3.63Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 0.74 · 95% CI 0.37 to 1.46Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 1.00 · 95% CI 0.50 to 2.00Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 0.75 · 95% CI 0.40 to 1.41Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 1.32 · 95% CI 0.70 to 2.48Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 0.64 · 95% CI 0.37 to 1.08Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 0.99 · 95% CI 0.58 to 1.69Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 1.03 · 95% CI 0.57 to 1.85Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 1.64 · 95% CI 0.90 to 2.97Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 1.25 · 95% CI 0.67 to 2.32Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 1.84 · 95% CI 0.98 to 3.45Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 0.76 · 95% CI 0.42 to 1.38Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 1.59 · 95% CI 0.87 to 2.91Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 1.04 · 95% CI 0.50 to 2.17Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 2.14 · 95% CI 1.02 to 4.50Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 2.11 · 95% CI 1.21 to 3.68Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 2.87 · 95% CI 1.64 to 5.03Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 1.65 · 95% CI 0.93 to 2.93Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 1.92 · 95% CI 1.07 to 3.43Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
SecondaryPhase 1: Serotype-specific Immunoglobin G (IgG) Geometric Mean Concentrations (GMCs) for the Serotypes Unique to V116

Serotype-specific pneumococcal IgG antibodies were measured using PnECL. Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.

Time frame:
30 days post vaccination
Reported as:
Geometric mean · μg/mL
Phase 1: Serotype-specific Immunoglobin G (IgG) Geometric Mean Concentrations (GMCs) for the Serotypes Unique to V116
μg/mLPhase 1: V116 0.5 mLPhase 1: V116 1.0 mLPhase 1: Pneumovax™23
Serotype 6A6.32 (NA to NA)8.08 (NA to NA)1.47 (NA to NA)
Serotype 15A8.87 (NA to NA)15.66 (NA to NA)1.76 (NA to NA)
Serotype 15C16.33 (NA to NA)18.26 (NA to NA)3.71 (NA to NA)
Serotype 16F1.27 (NA to NA)2.44 (NA to NA)0.37 (NA to NA)
Serotype 23A4.02 (NA to NA)4.03 (NA to NA)0.43 (NA to NA)
Serotype 23B5.52 (NA to NA)7.67 (NA to NA)1.61 (NA to NA)
Serotype 24F3.39 (NA to NA)6.79 (NA to NA)0.42 (NA to NA)
Serotype 312.68 (NA to NA)3.99 (NA to NA)0.29 (NA to NA)
Serotype 3511.89 (NA to NA)16.09 (NA to NA)1.29 (NA to NA)
Statistical analysis
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 4.29 · 95% CI 1.99 to 9.25Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 5.49 · 95% CI 2.53 to 11.91Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 5.05 · 95% CI 2.59 to 9.85Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 8.92 · 95% CI 4.55 to 17.50Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 4.40 · 95% CI 2.38 to 8.15Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 4.92 · 95% CI 2.64 to 9.16Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 3.41 · 95% CI 1.97 to 5.91Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 6.58 · 95% CI 3.78 to 11.45Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 9.42 · 95% CI 4.35 to 20.40Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 9.46 · 95% CI 4.34 to 20.62Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 3.43 · 95% CI 1.95 to 6.05Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 4.77 · 95% CI 2.69 to 8.45Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 8.06 · 95% CI 3.36 to 19.35Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 16.14 · 95% CI 6.68 to 39.01Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 9.14 · 95% CI 4.93 to 16.95Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 13.58 · 95% CI 7.28 to 25.32Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 9.24 · 95% CI 5.56 to 15.36Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmc ratio: 12.50 · 95% CI 7.49 to 20.87Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
SecondaryPhase 1: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the Common Serotypes in V116 and Pneumovax™23

GMTs for the serotypes common to V116 and Pneumovax™23 were determined using the MOPA. Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.

Time frame:
30 days post vaccination
Reported as:
Geometric mean · Titers
Phase 1: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the Common Serotypes in V116 and Pneumovax™23
TitersPhase 1: V116 0.5 mLPhase 1: V116 1.0 mLPhase 1: Pneumovax™23
Serotype 3242.35 (NA to NA)259.17 (NA to NA)243.66 (NA to NA)
Serotype 7F4503.32 (NA to NA)5672.08 (NA to NA)5122.36 (NA to NA)
Serotype 19A3312.61 (NA to NA)4595.55 (NA to NA)3475.22 (NA to NA)
Serotype 22F21336.23 (NA to NA)26003.97 (NA to NA)12905.25 (NA to NA)
Serotype 33F62540.43 (NA to NA)137389.68 (NA to NA)72703.24 (NA to NA)
Serotype 81830.31 (NA to NA)2321.18 (NA to NA)2598.16 (NA to NA)
Serotype 9N28204.72 (NA to NA)26659.08 (NA to NA)24483.35 (NA to NA)
Serotype 10A10338.92 (NA to NA)12377.52 (NA to NA)6623.80 (NA to NA)
Serotype 11A2531.25 (NA to NA)3152.05 (NA to NA)2836.72 (NA to NA)
Serotype 12F5171.95 (NA to NA)7279.62 (NA to NA)3036.31 (NA to NA)
Serotype 17F48838.60 (NA to NA)51152.97 (NA to NA)24816.34 (NA to NA)
Serotype 20A13910.60 (NA to NA)17799.33 (NA to NA)11430.20 (NA to NA)
Statistical analysis
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 0.99 · 95% CI 0.67 to 1.47Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 1.06 · 95% CI 0.72 to 1.57Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 0.88 · 95% CI 0.54 to 1.42Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 1.11 · 95% CI 0.68 to 1.80Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 0.95 · 95% CI 0.59 to 1.54Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 1.32 · 95% CI 0.81 to 2.15Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 1.65 · 95% CI 0.85 to 3.23Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 2.01 · 95% CI 1.03 to 3.96Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 0.86 · 95% CI 0.44 to 1.67Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 1.89 · 95% CI 0.97 to 3.69Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 0.70 · 95% CI 0.46 to 1.08Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 0.89 · 95% CI 0.58 to 1.38Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 1.15 · 95% CI 0.62 to 2.15Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 1.09 · 95% CI 0.58 to 2.04Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 1.56 · 95% CI 0.90 to 2.71Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 1.87 · 95% CI 1.08 to 3.23Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 0.89 · 95% CI 0.53 to 1.49Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 1.11 · 95% CI 0.66 to 1.87Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 1.70 · 95% CI 0.89 to 3.27Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 2.40 · 95% CI 1.24 to 4.62Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 1.97 · 95% CI 1.16 to 3.34Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 2.06 · 95% CI 1.21 to 3.51Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 1.22 · 95% CI 0.77 to 1.91Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 1.56 · 95% CI 0.99 to 2.45Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
SecondaryPhase 1: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the Unique Serotypes in V116 and Pneumovax™23

GMTs for the serotypes common to V116 and Pneumovax™23 were determined using the MOPA. Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.

Time frame:
30 days post vaccination
Reported as:
Geometric mean · Titers
Phase 1: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the Unique Serotypes in V116 and Pneumovax™23
TitersPhase 1: V116 0.5 mLPhase 1: V116 1.0 mLPhase 1: Pneumovax™23
Serotype 6A7182.41 (NA to NA)7407.66 (NA to NA)513.88 (NA to NA)
Serotype 15A19337.39 (NA to NA)24580.49 (NA to NA)2615.98 (NA to NA)
Serotype 15C20743.02 (NA to NA)27242.11 (NA to NA)9728.58 (NA to NA)
Serotype 16F11120.97 (NA to NA)17201.69 (NA to NA)2931.40 (NA to NA)
Serotype 23A26267.17 (NA to NA)36793.08 (NA to NA)1908.80 (NA to NA)
Serotype 23B5258.43 (NA to NA)8684.75 (NA to NA)220.48 (NA to NA)
Serotype 24F7593.39 (NA to NA)11867.21 (NA to NA)381.95 (NA to NA)
Serotype 317417.79 (NA to NA)7453.48 (NA to NA)128.36 (NA to NA)
Serotype 35B21103.18 (NA to NA)23826.47 (NA to NA)3044.94 (NA to NA)
Statistical analysis
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 13.98 · 95% CI 5.90 to 33.10Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 14.42 · 95% CI 6.05 to 34.35Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 7.39 · 95% CI 4.29 to 12.75Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 9.40 · 95% CI 5.42 to 16.28Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 2.13 · 95% CI 1.25 to 3.63Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 2.80 · 95% CI 1.64 to 4.79Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 3.79 · 95% CI 1.88 to 7.67Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 5.87 · 95% CI 2.88 to 11.94Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 13.76 · 95% CI 5.68 to 33.32Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 19.28 · 95% CI 7.91 to 47.00Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 23.85 · 95% CI 8.64 to 65.82Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 39.39 · 95% CI 14.15 to 109.65Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 19.88 · 95% CI 9.03 to 43.74Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 31.07 · 95% CI 13.98 to 69.03Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 57.79 · 95% CI 25.15 to 132.78Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 58.07 · 95% CI 25.10 to 134.33Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 0.5 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 6.93 · 95% CI 4.45 to 10.80Phase 1: V116 0.5 mL/Phase 1: Pneumovax™23
  • Phase 1: V116 1.0 mL vs Phase 1: Pneumovax™23 · Gmt ratio: 7.82 · 95% CI 5.00 to 12.24Phase 1: V116 1.0 mL/Phase 1: Pneumovax™23
SecondaryPhase 1: Geometric Mean Fold Rise (GMFR) From Baseline in GMTs of Serotype-specific OPA

GMTs for the serotypes in V116 and Pneumovax™23 were determined using the MOPA at baseline and 30 days post vaccination and derived from a cLDA model. The GMFR (Day 30 GMT/Day 1 GMT) from baseline (Day 1) to Day 30 of each pneumococcal IgG serotype was calculated.

Time frame:
Baseline (Day 1) and 30 days postvaccination
Reported as:
Geometric mean · Ratio
Phase 1: Geometric Mean Fold Rise (GMFR) From Baseline in GMTs of Serotype-specific OPA
RatioPhase 1: V116 0.5 mLPhase 1: V116 1.0 mLPhase 1: Pneumovax™23
Serotype 312.90 (8.95 to 18.59)10.68 (6.27 to 18.18)10.01 (6.62 to 15.14)
Serotype 7F15.64 (6.94 to 35.23)19.68 (9.96 to 38.87)34.18 (15.67 to 74.56)
Serotype 19A12.26 (7.03 to 21.38)18.34 (10.32 to 32.60)14.92 (7.84 to 28.42)
Serotype 22F92.21 (38.88 to 218.70)81.76 (32.42 to 206.23)32.64 (14.59 to 73.04)
Serotype 33F17.68 (10.86 to 28.78)34.83 (21.63 to 56.09)20.24 (11.07 to 37.02)
Serotype 839.67 (21.83 to 72.09)50.01 (25.73 to 97.20)72.24 (38.21 to 136.59)
Serotype 9N22.91 (10.93 to 48.00)19.80 (8.34 to 47.04)27.38 (13.87 to 54.03)
Serotype 10A12.69 (5.39 to 29.87)18.21 (8.76 to 37.85)10.35 (5.00 to 21.41)
Serotype 11A7.46 (3.40 to 16.39)8.23 (4.46 to 15.21)7.64 (4.20 to 13.93)
Serotype 12F360.69 (192.76 to 674.93)448.73 (243.29 to 827.65)162.71 (85.83 to 308.43)
Serotype 17F36.57 (17.73 to 75.45)37.33 (20.19 to 69.04)20.54 (11.70 to 36.08)
Serotype 20A15.67 (8.21 to 29.92)19.20 (10.52 to 35.07)14.91 (8.60 to 25.83)
Serotype 6A311.54 (171.83 to 565.18)375.42 (194.76 to 723.64)20.95 (9.44 to 46.47)
Serotype 15A31.56 (12.49 to 79.74)29.31 (13.47 to 63.79)5.53 (2.96 to 10.35)
Serotype 15C37.97 (13.68 to 105.40)58.39 (20.58 to 165.67)10.58 (6.14 to 18.23)
Serotype 16F16.82 (7.30 to 38.75)25.99 (10.54 to 64.09)4.30 (2.59 to 7.12)
Serotype 23A380.08 (136.77 to 1056.21)269.90 (86.95 to 837.80)17.52 (6.87 to 44.65)
Serotype 23B99.58 (36.09 to 274.72)157.02 (61.06 to 403.76)5.39 (2.92 to 9.95)
Serotype 24F14.86 (5.86 to 37.70)23.51 (9.64 to 57.34)1.24 (0.76 to 2.03)
Serotype 3195.53 (36.62 to 249.17)94.51 (39.26 to 227.50)3.23 (1.52 to 6.86)
Serotype 35B13.68 (7.26 to 25.79)12.56 (8.48 to 18.61)1.73 (1.45 to 2.06)
Serotype 6C41.71 (14.41 to 120.73)65.05 (23.86 to 177.35)2.82 (1.46 to 5.43)
Serotype 15B78.68 (25.58 to 242.03)89.25 (30.60 to 260.27)33.11 (13.27 to 82.61)
Serotype 20B3.78 (1.97 to 7.26)4.17 (2.05 to 8.47)5.01 (2.46 to 10.23)
SecondaryPhase 1: Geometric Mean Fold Rise (GMFR) From Baseline in GMCs of Serotype-specific IgG

GMCs for the serotypes in V116 and Pneumovax™23 were measured by PnECL at baseline and 30 days post vaccination and derived from a cLDA model. The GMFR (Day 30 GMC/Day 1 GMC) from baseline (Day 1) to Day 30 of each pneumococcal IgG serotype was calculated.

Time frame:
Baseline (Day 1) and 30 days post vaccination
Reported as:
Geometric mean · Ratio
Phase 1: Geometric Mean Fold Rise (GMFR) From Baseline in GMCs of Serotype-specific IgG
RatioPhase 1: V116 0.5 mLPhase 1: V116 1.0 mLPhase 1: Pneumovax™23
Serotype 35.36 (3.90 to 7.35)5.94 (4.05 to 8.71)4.97 (3.39 to 7.27)
Serotype 7F8.38 (5.30 to 13.25)16.00 (10.28 to 24.90)7.44 (5.05 to 10.97)
Serotype 19A4.67 (3.03 to 7.21)7.28 (4.63 to 11.45)3.66 (2.66 to 5.04)
Serotype 22F19.51 (11.64 to 32.69)21.83 (13.51 to 35.29)24.34 (12.30 to 48.18)
Serotype 33F9.33 (5.62 to 15.49)16.28 (10.36 to 25.58)11.75 (7.66 to 18.03)
Serotype 813.86 (8.94 to 21.49)22.89 (15.29 to 34.27)25.99 (15.35 to 44.00)
Serotype 9N12.90 (8.60 to 19.36)20.85 (13.11 to 33.16)14.37 (8.41 to 24.55)
Serotype 10A11.36 (6.61 to 19.52)16.10 (9.76 to 26.57)9.58 (6.94 to 13.24)
Serotype 11A2.71 (1.70 to 4.33)7.18 (3.96 to 13.02)5.17 (3.24 to 8.24)
Serotype 12F10.35 (6.36 to 16.85)22.71 (13.35 to 38.61)9.75 (5.37 to 17.71)
Serotype 17F19.23 (11.44 to 32.34)22.52 (14.61 to 34.73)10.07 (6.80 to 14.91)
Serotype 20A10.81 (6.67 to 17.50)11.18 (7.38 to 16.93)5.60 (3.58 to 8.77)
Serotype 6A23.58 (12.37 to 44.95)29.48 (18.01 to 48.26)5.66 (3.29 to 9.76)
Serotype 15A14.61 (8.07 to 26.45)28.84 (17.91 to 46.44)3.02 (1.87 to 4.88)
Serotype 15C31.93 (18.64 to 54.69)37.55 (20.18 to 69.88)7.94 (5.56 to 11.36)
Serotype 16F4.39 (2.71 to 7.11)10.80 (7.22 to 16.15)1.69 (1.16 to 2.45)
Serotype 23A23.43 (12.21 to 44.99)22.53 (11.84 to 42.86)2.75 (1.83 to 4.13)
Serotype 23B9.03 (4.99 to 16.36)15.56 (8.88 to 27.27)2.66 (1.92 to 3.68)
Serotype 24F11.18 (5.18 to 24.13)19.44 (11.30 to 33.47)1.26 (0.79 to 2.03)
Serotype 3112.83 (7.24 to 22.75)19.71 (12.90 to 30.13)1.77 (1.19 to 2.63)
Serotype 35B9.77 (5.70 to 16.73)11.33 (7.01 to 18.31)0.96 (0.86 to 1.06)
Serotype 6C6.52 (3.64 to 11.70)9.48 (5.47 to 16.42)2.22 (1.61 to 3.07)
Serotype 15B12.54 (6.73 to 23.36)11.96 (6.32 to 22.65)8.05 (5.67 to 11.42)
SecondaryPhase 2: Serotype-specific IgG GMCs for the Common Serotypes in V116 and Pneumovax™23

Serotype-specific pneumococcal IgG antibodies were measured using PnECL. Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.

Time frame:
30 days post vaccination
Reported as:
Geometric mean · μg/mL
Phase 2: Serotype-specific IgG GMCs for the Common Serotypes in V116 and Pneumovax™23
μg/mLPhase 2: V116Phase 2: Pneumovax™23
Serotype 30.78 (NA to NA)0.72 (NA to NA)
Serotype 7F4.98 (NA to NA)4.07 (NA to NA)
Serotype 19A7.77 (NA to NA)6.26 (NA to NA)
Serotype 22F3.81 (NA to NA)2.79 (NA to NA)
Serotype 33F11.89 (NA to NA)13.82 (NA to NA)
Serotype 89.86 (NA to NA)10.30 (NA to NA)
Serotype 9N7.18 (NA to NA)5.51 (NA to NA)
Serotype 10A10.78 (NA to NA)5.89 (NA to NA)
Serotype 11A5.16 (NA to NA)3.35 (NA to NA)
Serotype 12F1.56 (NA to NA)0.68 (NA to NA)
Serotype 17F12.85 (NA to NA)7.06 (NA to NA)
Serotype 20A20.59 (NA to NA)9.09 (NA to NA)
Statistical analysis
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmc ratio: 1.08 · 95% CI 0.90 to 1.30Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmc ratio: 1.23 · 95% CI 0.99 to 1.52Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmc ratio: 1.24 · 95% CI 1.02 to 1.52Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmc ratio: 1.36 · 95% CI 1.06 to 1.75Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmc ratio: 0.86 · 95% CI 0.69 to 1.06Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmc ratio: 0.96 · 95% CI 0.78 to 1.18Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmc ratio: 1.30 · 95% CI 1.04 to 1.64Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmc ratio: 1.83 · 95% CI 1.44 to 2.32Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmc ratio: 1.54 · 95% CI 1.27 to 1.86Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmc ratio: 2.30 · 95% CI 1.75 to 3.04Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmc ratio: 1.82 · 95% CI 1.49 to 2.22Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmc ratio: 2.27 · 95% CI 1.81 to 2.83Phase 2: V116/Phase 2: Pneumovax™23
SecondaryPhase 2: Serotype-specific IgG GMCs for the Serotypes Unique to V116

Serotype-specific pneumococcal IgG antibodies were measured using PnECL. Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.

Time frame:
30 days post vaccination
Reported as:
Geometric mean · μg/mL
Phase 2: Serotype-specific IgG GMCs for the Serotypes Unique to V116
μg/mLPhase 2: V116Phase 2: Pneumovax™23
Serotype 6A4.06 (NA to NA)1.07 (NA to NA)
Serotype 15A13.14 (NA to NA)1.71 (NA to NA)
Serotype 15C11.91 (NA to NA)3.62 (NA to NA)
Serotype 16F2.17 (NA to NA)0.25 (NA to NA)
Serotype 23A3.32 (NA to NA)0.42 (NA to NA)
Serotype 23B5.18 (NA to NA)0.92 (NA to NA)
Serotype 24F6.11 (NA to NA)0.25 (NA to NA)
Serotype 313.15 (NA to NA)0.31 (NA to NA)
Serotype 35B24.55 (NA to NA)1.34 (NA to NA)
Statistical analysis
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmc ratio: 3.77 · 95% CI 2.95 to 4.84Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmc ratio: 7.68 · 95% CI 6.12 to 9.64Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmc ratio: 3.29 · 95% CI 2.60 to 4.17Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmc ratio: 8.65 · 95% CI 7.19 to 10.41Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmc ratio: 7.83 · 95% CI 6.20 to 9.90Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmc ratio: 5.61 · 95% CI 4.53 to 6.94Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmc ratio: 23.99 · 95% CI 19.35 to 29.74Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value was estimated from a cLDA model. · p = <0.001 · Gmc ratio: 10.13 · 95% CI 8.32 to 12.33Phase 2: V116/Phase 2: Pneumovax™23
  • Phase 2: V116 vs Phase 2: Pneumovax™23 · P-value is estimated from a cLDA model. · p = <0.001 · Gmc ratio: 18.29 · 95% CI 15.59 to 21.45Phase 2: V116/Phase 2: Pneumovax™23
SecondaryPhase 2: Geometric Mean Fold Rise (GMFR) From Baseline in GMTs of Serotype-specific OPA

GMTs for the serotypes in V116 and Pneumovax™23 were determined using the MOPA at baseline and at 30 days post vaccination and derived from a cLDA model. The GMFR for each pneumococcal IgG serotype was calculated as Day 30 GMT/Day 1 GMT.

Time frame:
Baseline (Day 1) and 30 days post vaccination
Reported as:
Geometric mean · Ratio
Phase 2: Geometric Mean Fold Rise (GMFR) From Baseline in GMTs of Serotype-specific OPA
RatioPhase 2: V116Phase 2: Pneumovax™23
Serotype 312.03 (10.04 to 14.41)10.96 (9.25 to 13.00)
Serotype 7F31.07 (22.87 to 42.22)22.52 (17.23 to 29.45)
Serotype 19A13.05 (10.22 to 16.66)10.26 (8.31 to 12.67)
Serotype 22F52.66 (37.40 to 74.14)46.34 (33.34 to 64.41)
Serotype 33F13.47 (10.47 to 17.32)14.04 (11.23 to 17.53)
Serotype 839.06 (30.34 to 50.28)40.06 (31.59 to 50.80)
Serotype 9N33.51 (24.38 to 46.04)29.38 (21.67 to 39.82)
Serotype 10A12.34 (8.79 to 17.31)8.12 (6.03 to 10.94)
Serotype 11A33.21 (25.13 to 43.88)12.29 (9.41 to 16.05)
Serotype 12F150.08 (112.83 to 199.61)57.03 (42.59 to 76.35)
Serotype 17F40.71 (30.35 to 54.60)25.68 (19.56 to 33.73)
Serotype 20A20.48 (16.11 to 26.02)12.16 (9.58 to 15.43)
Serotype 6A79.16 (58.28 to 107.51)11.30 (8.42 to 15.16)
Serotype 15A26.66 (20.16 to 35.25)3.93 (3.18 to 4.87)
Serotype 15C65.18 (46.91 to 90.58)23.73 (16.98 to 33.15)
Serotype 16F56.50 (41.53 to 76.85)3.54 (2.61 to 4.81)
Serotype 23A237.14 (166.28 to 338.22)10.65 (7.42 to 15.29)
Serotype 23B97.79 (71.94 to 132.92)4.62 (3.58 to 5.96)
Serotype 24F48.78 (35.07 to 67.84)1.52 (1.18 to 1.97)
Serotype 3192.00 (66.09 to 128.07)3.25 (2.51 to 4.21)
Serotype 35B12.41 (10.08 to 15.27)1.53 (1.33 to 1.75)
Serotype 6C19.41 (13.65 to 27.61)4.24 (3.09 to 5.84)
Serotype 15B24.32 (17.88 to 33.08)25.73 (19.14 to 34.58)
Serotype 20B7.21 (5.68 to 9.17)5.35 (4.08 to 7.01)
SecondaryPhase 2: GMFR From Baseline in GMCs of Serotype-specific IgG

GMCs for each serotype common in V116 and Pneumovax™23 were measured using PnECL at baseline and 30 days post vaccination and derived from a cLDA model. The GMFR for each pneumococcal IgG serotype was calculated as Day 30 GMC/Day 1 GMC.

Time frame:
Baseline (Day 1) and 30 days post vaccination
Reported as:
Geometric mean · Ratio
Phase 2: GMFR From Baseline in GMCs of Serotype-specific IgG
RatioPhase 2: V116Phase 2: Pneumovax™23
Serotype 35.23 (4.52 to 6.06)4.56 (3.98 to 5.21)
Serotype 7F9.96 (8.40 to 11.81)8.28 (7.06 to 9.71)
Serotype 19A5.29 (4.51 to 6.21)4.12 (3.60 to 4.71)
Serotype 22F12.45 (10.07 to 15.39)9.04 (7.53 to 10.86)
Serotype 33F9.94 (8.26 to 11.97)11.63 (9.87 to 13.71)
Serotype 814.53 (11.92 to 17.72)15.51 (13.06 to 18.40)
Serotype 9N17.77 (14.62 to 21.61)11.80 (9.92 to 14.04)
Serotype 10A17.32 (14.41 to 20.82)9.29 (7.92 to 10.90)
Serotype 11A7.71 (6.56 to 9.07)4.72 (4.12 to 5.41)
Serotype 12F13.72 (11.13 to 16.91)6.14 (5.11 to 7.37)
Serotype 17F20.26 (17.03 to 24.11)11.11 (9.54 to 12.95)
Serotype 20A14.95 (12.53 to 17.84)6.30 (5.41 to 7.33)
Serotype 6A13.35 (10.90 to 16.35)3.56 (3.03 to 4.19)
Serotype 15A23.94 (19.89 to 28.81)3.02 (2.63 to 3.47)
Serotype 15C22.35 (18.49 to 27.01)7.28 (6.17 to 8.60)
Serotype 16F12.42 (10.62 to 14.52)1.51 (1.37 to 1.66)
Serotype 23A20.27 (16.82 to 24.43)2.66 (2.30 to 3.06)
Serotype 23B13.50 (11.25 to 16.21)2.51 (2.21 to 2.85)
Serotype 24F25.20 (20.48 to 31.02)1.08 (1.02 to 1.14)
Serotype 3115.89 (13.47 to 18.76)1.62 (1.46 to 1.81)
Serotype 35B18.72 (15.89 to 22.05)1.04 (0.98 to 1.10)
Serotype 6C5.78 (4.79 to 6.97)1.67 (1.52 to 1.85)
Serotype 15B9.95 (8.28 to 11.95)8.87 (7.52 to 10.47)
SecondaryPhase 2: Percentage of Participants Who Achieve a ≥4-fold Increase in Serotype-specific OPA Responses From Prevaccination (Baseline [Day 1]) to 30 Days Post Vaccination

The percentage of participants with ≥4-fold rise from baseline (Day 1) to Day 30 in GMTs of each pneumococcal serotype was calculated. Titer levels were determined by the MOPA and derived from a cLDA model.

Time frame:
Baseline (Day 1) and 30 days post vaccination
Reported as:
Number · Percentage of Participants
Phase 2: Percentage of Participants Who Achieve a ≥4-fold Increase in Serotype-specific OPA Responses From Prevaccination (Baseline [Day 1]) to 30 Days Post Vaccination
Percentage of ParticipantsPhase 2: V116Phase 2: Pneumovax™23
Serotype 374.8 (68.8 to 80.2)75.7 (69.7 to 81.1)
Serotype 7F74.2 (68.1 to 79.6)77.0 (71.1 to 82.2)
Serotype 19A66.9 (60.6 to 72.9)67.1 (60.7 to 73.1)
Serotype 22F81.3 (75.7 to 86.1)79.3 (73.5 to 84.3)
Serotype 33F68.4 (62.0 to 74.3)75.7 (69.5 to 81.1)
Serotype 880.9 (75.2 to 85.7)85.5 (80.3 to 89.7)
Serotype 9N77.3 (71.3 to 82.5)79.5 (73.7 to 84.5)
Serotype 10A59.9 (52.4 to 67.1)55.2 (47.5 to 62.7)
Serotype 11A80.3 (74.6 to 85.1)62.9 (56.3 to 69.2)
Serotype 12F90.2 (85.4 to 93.8)82.9 (77.3 to 87.6)
Serotype 17F85.2 (80.1 to 89.5)80.9 (75.2 to 85.7)
Serotype 20A83.6 (78.3 to 88.1)69.4 (63.0 to 75.2)
Serotype 6A83.2 (77.8 to 87.7)58.8 (52.2 to 65.2)
Serotype 15A86.6 (81.3 to 90.8)39.3 (32.7 to 46.3)
Serotype 15C88.5 (83.6 to 92.3)71.0 (64.4 to 76.9)
Serotype 16F85.4 (80.1 to 89.7)30.2 (24.2 to 36.8)
Serotype 23A93.3 (89.1 to 96.3)48.7 (41.6 to 55.9)
Serotype 23B87.4 (82.4 to 91.4)40.4 (33.9 to 47.0)
Serotype 24F82.8 (77.2 to 87.5)15.3 (10.6 to 21.0)
Serotype 3186.6 (81.3 to 90.8)30.1 (24.0 to 36.9)
Serotype 35B73.2 (67.0 to 78.9)11.3 (7.5 to 16.2)
Serotype 6C58.4 (51.8 to 64.9)33.8 (27.7 to 40.3)
Serotype 15B71.0 (64.6 to 76.8)75.3 (69.1 to 80.8)
Serotype 20B52.8 (46.2 to 59.4)44.1 (37.5 to 50.8)

Adverse events

Collected over Up to approximately 195 days post-vaccination for Phase 1 and up to approximately 293 days post-vaccination for Phase 2.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: V116 0.5 mL0/30 (0%)0/30 (0%)23/30 (76.7%)
Phase 1: V116 1.0 mL0/30 (0%)0/30 (0%)24/30 (80%)
Phase 1: PPSV230/30 (0%)0/30 (0%)21/30 (70%)
Phase 2: V1161/254 (0.4%)4/254 (1.6%)159/254 (62.6%)
Phase 2: PPSV230/256 (0%)3/254 (1.2%)133/254 (52.4%)
Most frequent serious events
Most frequent serious events
EventPhase 1: V116 0.5 mLPhase 1: V116 1.0 mLPhase 1: PPSV23Phase 2: V116Phase 2: PPSV23
Acute coronary syndromeCardiac disorders0/300/300/300/2541/254
Atrial fibrillationCardiac disorders0/300/300/301/2540/254
Gastrointestinal haemorrhageGastrointestinal disorders0/300/300/301/2540/254
COVID-19Infections and infestations0/300/300/301/2540/254
Staphylococcal bacteraemiaInfections and infestations0/300/300/300/2541/254
Urinary tract infectionInfections and infestations0/300/300/300/2541/254
Rotator cuff syndromeMusculoskeletal and connective tissue disorders0/300/300/301/2540/254
Cervical radiculopathyNervous system disorders0/300/300/301/2540/254
Acute kidney injuryRenal and urinary disorders0/300/300/300/2541/254
Most frequent other events
Most frequent other events
EventPhase 1: V116 0.5 mLPhase 1: V116 1.0 mLPhase 1: PPSV23Phase 2: V116Phase 2: PPSV23
Injection site painGeneral disorders22/3023/3017/30118/25496/254
HeadacheNervous system disorders10/306/305/3047/25441/254
MyalgiaMusculoskeletal and connective tissue disorders8/309/304/3033/25426/254
FatigueGeneral disorders8/308/305/3050/25432/254
Injection site erythemaGeneral disorders3/307/306/3026/25417/254
Injection site swellingGeneral disorders6/305/304/3030/25420/254
ArthralgiaMusculoskeletal and connective tissue disorders5/303/302/3011/25412/254
Injection site bruisingGeneral disorders0/302/301/301/2540/254
PyrexiaGeneral disorders0/300/302/301/2540/254
Upper respiratory tract infectionInfections and infestations1/302/300/300/2540/254

Baseline characteristics

Age, Continuous
Age, Continuous(years)Phase 1: V116 0.5 mLPhase 1: V116 1.0 mLPhase 1: Pneumovax™23Phase 2: V116Phase 2: Pneumovax™23Total
Mean37.8 ± 7.434.7 ± 8.935.2 ± 8.261.3 ± 7.061.2 ± 7.357.5 ± 11.7
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: V116 0.5 mLPhase 1: V116 1.0 mLPhase 1: Pneumovax™23Phase 2: V116Phase 2: Pneumovax™23Total
Female161924142140341
Male14116112116259
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1: V116 0.5 mLPhase 1: V116 1.0 mLPhase 1: Pneumovax™23Phase 2: V116Phase 2: Pneumovax™23Total
Hispanic or Latino141313107107254
Not Hispanic or Latino161717147147344
Unknown or Not Reported000022
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1: V116 0.5 mLPhase 1: V116 1.0 mLPhase 1: Pneumovax™23Phase 2: V116Phase 2: Pneumovax™23Total
American Indian or Alaska Native000213
Asian112239
Native Hawaiian or Other Pacific Islander000101
Black or African American644253069
White232324224220514
More than one race020024
Unknown or Not Reported000000
08

Study locations

20 sites
  • Simon Williamson Clinic ( Site 0004)
    Birmingham, Alabama 35211, United States
  • Central Arizona Medical Associates ( Site 0003)
    Mesa, Arizona 85206, United States
  • Clinical Research of South Florida ( Site 0008)
    Coral Gables, Florida 33134, United States
  • Indago Research & Health Center, Inc ( Site 0011)
    Hialeah, Florida 33012, United States
  • Research Centers of America, LLC ( Site 0001)
    Hollywood, Florida 33024, United States
  • QPS Miami Research Associates ( Site 0016)
    Miami, Florida 33143, United States
  • L&C Professional Medical Research Institute ( Site 0009)
    Miami, Florida 33144, United States
  • Advanced Medical Research Institute ( Site 0010)
    Miami, Florida 33174, United States
  • Optimal Research ( Site 0006)
    Peoria, Illinois 61614, United States
  • Benchmark Research ( Site 0012)
    Metairie, Louisiana 70006, United States
  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division ( Site 0018)
    Troy, Michigan 48098, United States
  • Meridian Clinical Research, LLC ( Site 0024)
    Norfolk, Nebraska 68701, United States
  • Wake Research Clinical Research Center of Nevada, LLC ( Site 0014)
    Las Vegas, Nevada 89104, United States
  • Meridian Clinical Research, LLC ( Site 0025)
    Endwell, New York 13760, United States
  • Rochester Clinical Research, Inc. ( Site 0002)
    Rochester, New York 14609, United States
  • PriMED Clinical Research ( Site 0021)
    Dayton, Ohio 45419, United States
  • Advanced Medical Research ( Site 0017)
    Maumee, Ohio 43537, United States
  • Kaiser Permanente Center for Health Research ( Site 0015)
    Portland, Oregon 97227, United States
  • Diagnostics Research Group ( Site 0013)
    San Antonio, Texas 78229, United States
  • Advanced Clinical Research ( Site 0022)
    West Jordan, Utah 84088, United States
09

References and documents

Publications

  • Platt H, Omole T, Cardona J, Fraser NJ, Mularski RA, Andrews C, Daboul N, Gallagher N, Sapre A, Li J, Polis A, Fernsler D, Tamms G, Xu W, Murphy R, Skinner J, Joyce J, Musey L. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial. Lancet Infect Dis. 2023 Feb;23(2):233-246. doi: 10.1016/S1473-3099(22)00526-6. Epub 2022 Sep 15. PubMed 36116461 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Jul 2021, 19 months.

Results were first posted in Aug 2022, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2019
First posted
Nov 19, 2019
StartActual
Dec 6, 2019
Primary completionActual
Jul 12, 2021
CompletionActual
Jul 12, 2021
Results first posted
Aug 2, 2022
Last update
Sep 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04168190
Responsible party
Sponsor
First posted
Nov 19, 2019
Start date
Dec 6, 2019
Primary completion
Jul 12, 2021
Completion
Jul 12, 2021
Results posted
Aug 2, 2022
Last update
Sep 16, 2022

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 21-Valent Conjugate Vaccine

Start the discussion